Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has received an average recommendation of “Moderate Buy” from the eight brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $20.1429.

LXEO has been the subject of several research analyst reports. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Finally, Chardan Capital restated a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a research report on Monday, May 11th.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the sale, the chief executive officer owned 340,106 shares in the company, valued at $1,935,203.14. This represents a 13.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 59,644 shares of company stock valued at $336,462. 2.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXEO. AQR Capital Management LLC lifted its position in Lexeo Therapeutics by 370.0% in the 1st quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after buying an additional 39,627 shares in the last quarter. Millennium Management LLC lifted its position in Lexeo Therapeutics by 654.8% in the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after buying an additional 929,538 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Lexeo Therapeutics in the 1st quarter worth approximately $85,000. Rhumbline Advisers lifted its position in Lexeo Therapeutics by 19.8% in the 1st quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after buying an additional 4,995 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in Lexeo Therapeutics in the 2nd quarter worth approximately $50,000. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Price Performance

NASDAQ LXEO opened at $4.93 on Friday. Lexeo Therapeutics has a 12 month low of $3.60 and a 12 month high of $10.99. The firm has a market capitalization of $387.10 million, a PE ratio of -3.40 and a beta of 1.38. The company’s 50 day simple moving average is $5.40 and its 200 day simple moving average is $6.90.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Sell-side analysts anticipate that Lexeo Therapeutics will post -1.23 earnings per share for the current fiscal year.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.